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Purpose: Although most colorectal malignancies are adenocarcinomas from mucosa, various types of malignant and be-
nign tumors can develop. Due to extremely low incidence, little research has been conducted. The purpose was to assess 
incidence and compare it according to demographic factors. 
Methods: Data from the Korea National Cancer Registry from 2007 to 2016 were used. The crude incidence, age-standard 
incidence rate (ASR) of colorectal nonadenocarcinomas were calculated.
Results: Over 11 years, there were 267,142 patients with colorectal malignancies. The patients of 14,495 (5.43%) were di-
agnosed with nonadenocarcinoma. The ASR was 2.52 per 100,000 in men and 1.56 in women. Lesions were classified ac-
cording to histologic categories; neuroendocrine tumor (NET) was the most common malignancy (10,919 [75.33%]). 
Nonadenocarcinoma was the most common in 40s and 50s (40 to 49 years, 3,530 [24.35%]; 50 to 59 years, 3,991 
[27.53%]). Lymphoma was high (54.46%) in patients in teenagers. Proportion of NET decreased with age and that of car-
cinoma increased with age. Carcinoma, sarcoma, and lymphoma were more common among men and melanoma was 
more common among women. The most common site was the rectum (11,066 [76.34%]). Lymphoma occurred more fre-
quently in proximal colon. Melanoma, gastrointestinal stromal tumor, and NET occurred mostly in rectum. A total of 
10,155 patients (70.06%) were classified as having localized disease.
Conclusion: This study is meaningful as it is the first study to examine incidence of colorectal nonadenocarcinoma. Dif-
ferences in incidence of different lesions based on demographic factors were identified. This study will play a role in can-
cer prevention and diagnosis projects.
Keywords: Colon neoplasms; Incidence; Sarcoma; Neuroendocrine tumors; Carcinoma
INTRODUCTION
Colorectal cancer has one of the highest incidences worldwide. It 
is the second most common malignancy in Europe and North 
America, following skin cancer [1, 2]. Additionally, the incidence 
of colorectal cancer is increasing in Asia, including Korea. It is the 
second most common cancer among men in Korea and the third 
most common among women [3]. Most colon cancers are adeno-
carcinomas originating from the colon mucosa. However, the co-
lon is composed of various cell types other than mucosal cells. 
Therefore, various types of malignant and benign tumors, such as 
neuroendocrine tumors (NETs), gastrointestinal stromal tumors 
(GISTs), lymphomas, sarcomas, and lipomas may occur. How-
ever, since colorectal nonadenocarcinomas arise very infrequently, 
it is difficult to obtain a sufficiently large sample to perform com-
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prehensive studies. Studies about nonadenocarcinoma have been 
rarely conducted for this reason, not only in Korea but also in 
other countries.
In the United States, the incidence of NET is 0.3 per 100,000 in 
the colon and 1.1 per 100,000 in the rectum [4], and a previous 
study found that neuroendocrine cancer in the colon accounts for 
0.6% of total colon malignancies [5]. The incidence of squamous 
cell carcinoma of the colon is also very low, accounting for 0.01% 
to 0.85% of all colorectal cancers [6]; fewer than 100 cases of 
squamous cell carcinoma have been reported thus far [7]. Sar-
coma that arises in the colon is reported to account for 0.1% of all 
colon malignancies [8]. Leiomyosarcoma accounts for 57.5% of 
colonic sarcomas and sarcoma accounts for 16.2% [9]. Colon 
melanoma is extremely rare; 13 cases have been reported, and 
there is no study about the incidence of colon melanoma [10]. 
Colonic lymphoma was reported to account for 0.1% to 0.6% of 
colorectal cancer [11]. There was no study about incidence of 
colorectal nonadenocarcinoma with nationwide data.
Some studies have examined colorectal nonadenocarcinoma, 
but studies about incidence are rare because of its low incidence. 
Therefore, the purpose of this study was to assess the incidence 
and identify the differences in the incidences of colorectal nonad-
enocarcinomas according to demographic factors using large-
scale data from the Korea National Cancer Registry.
METHODS
We used data from the National Cancer Registry, which is man-
aged by the Korea National Cancer Center. We included the data 
of patients from 2007 to 2016 with “Korean Standard Classifica-
tion of Diseases Diagnostic Code” of C18, C19, or C20, which in-
dicate malignancy of the colon and rectum. Patients were classi-
fied pathologically using the Korean morphologic code (M code) 
[12]. Patients with an M code indicating adenocarcinoma were 
excluded. The M code is shown in Fig. 1. The M code consists of 
5-unit numbers. The first 4 digits represent the histology of the 
neoplasm and the 5th digit represents its behavior. The M codes 
included in this study are listed in Table 1. 
The purpose of this study was to investigate the incidence of 
colorectal nonadenocarcinoma. Therefore, most statistical analy-
ses were performed to calculate the incidence and percentage. 
The variables used were sex, age, histological category, anatomical 
location, and SEER (Surveillance, Epidemiology and End Results) 
stage. To determine the incidence, the crude incidence and age-
standard incidence were calculated. The population statistics in 
2010 were used to calculate the age-standard incidence, and 95% 
confidence intervals were calculated. Cross-analysis was used to 
determine the characteristics of each histologic category accord-
ing to age, sex, and anatomical location. 
This study was approved by Institutional Review Board of Na-
tional Health Insurance Service Ilsan Hospital (NHIMC 2018-07-
007). The waiver of informed consent was granted for the collec-
tion of data from the existing medical records of patients.
RESULTS
We first identified the total number of patients with nonadeno-
carcinoma of the colon and rectum from 2007 to 2016 in the Ko-
rea National Cancer Registry data. Over 11 years, 267,142 patients 
were diagnosed with colorectal malignancy. Among these, there 
were 14,495 (5.43%) nonadenocarcinoma patients. We divided 
the patients into 6 categories based on histologic diagnosis of 
nonadenocarcinoma. Each category and histologic diagnosis with 
M code are described in Table 1. 
Demographic features of nonadenocarcinoma patients are de-
scribed in Table 2. The majority of patients were men (8,760 
[60.43%]). NET was the most common nonadenocarcinoma his-
tology (10,919 [75.33%]), followed by carcinoma (1,454 
[10.03%]), lymphoma (1,431 [9.87%]), GIST (393 [2.71%]), sar-
coma (156 [1.08%]), and melanoma (142 [0.98%]). Patients in 
their 40s and 50s accounted for the highest percentage of patients 
(40 to 49 years, 3,530 [24.35%]; 50 to 59 years, 3,991 [27.53%]). 
Most nonadenocarcinomas occurred in the rectum (Table 2).
The number of patients and incidence of each nonadenocarci-
noma were analyzed by sex (Tables 3, 4). The age-standardized 
incidence rates of nonadenocarcinoma were 2.52 per 100,000 
men and 1.56 per 100,000 women. The proportion of nonadeno-
carcinoma among total colon malignancies was similar in both 
sexes but slightly higher in men (men vs. women, 5.46% vs. 
5.37%). NET was the most common histology in both sexes. The 
proportions of the histologic categories in both sexes were similar, 
although most were slightly more common among men. How-
ever, melanoma tended to be more common among women 
(women, 90 [63.38%]; men, 52 [36.62%]).
We also analyzed incidence by age. The proportion of nonade-
nocarcinomas among total colorectal malignancies was higher in 
younger patients and decreased with increasing age (Table 5). 
NETs were the most common in most age groups. However, lym-
phoma was characteristically high in patients 10 to 19 years of age 
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counted for 54.46% of tumors. As patient age increased, the pro-
portion of NET gradually decreased, and the proportion of carci-
noma and melanoma increased. Carcinoma-except adenocarci-
noma accounted for 46.68% of nonadenocarcinomas in patients 
80 years and older. 
We compared the incidence of nonadenocarcinomas according 
to the anatomical location of the colon (Fig. 2). Lymphoma was 
the most common lesion in the proximal colon, including the ce-
cum and ascending colon (cecum, 420 [81.24%]; ascending colon, 
250 [47.80%]). NET, which was the most frequent nonadenocar-
cinoma, was also the most frequent lesion in the appendix and 
rectum (appendix, 170 [70.54%]; rectum, 9,807 [88.62%]). Mela-
noma occurred in the rectum (136 [97.84%]), except for 3 cases 
each involving the sigmoid colon and rectosigmoid junction.  
The National Cancer Registry uses the SEER staging system. 
SEER stage is composed of localized disease, regional disease, dis-
tant disease, and unstaged disease. Among 14,495 patients, 10,155 
patients (70.06%) were classified as having localized disease, 1,221 
(8.42%) as having regional disease, and 1,138 (7.85%) as having 
distant disease. The SEER stage of each category of nonadenocar-
cinoma is shown in Fig. 3. NETs were mostly localized, but carci-
nomas, lymphomas, and melanomas were more commonly diag-
Table 1. Histologic diagnosis and categorization of nonadenocarcinoma of colon and rectum
Category Histologic type
1. Carcinoma
   1.1. Squamous cell carcinoma
   1.2. Other specified carcinoma
Verrucous carcinoma (M80513), Papillary squamous cell carcinoma (M80523), Squamous cell carcinoma (M80703), 
Squamous cell carcinoma, keratinizing (M80713), Squamous cell carcinoma, large cell, nonkeratinizing (M80723), 
Squamous cell carcinoma, microinvasive (M80763), Basaloid cell carcinoma (M80833)
Carcinoma (M80103), Undifferentiated carcinoma (M80203), Anaplastic carcinoma (M80213), Pleomorphic carcinoma 
(M80223), Cloacogenic carcinoma (M81243), Transitional cell carcinoma (M81203), Adenosquamous carcinoma 
(M85603), Carcinosarcoma (M89803)
2. Neuroendocrine tumor (NET)
   2.1. NET
   2.2. Neuroendocrine carcinoma
Neuroendocrine tumor (M82403)
Large cell neuroendocrine carcinoma (M80133), Small cell carcinoma (M80413), Mixed adenoneuroendocrine  
carcinoma (M82443), Neuroendocrine carcinoma (M82463)
3. Sarcoma
   3.1. Sarcoma, not otherwise specified
   3.2. Leiomyosarcoma
   3.3. Other specified sarcoma
Sarcoma (M88003), Spindle cell sarcoma (M88013), Giant cell sarcoma (M88023), Epithelioid sarcoma (M88043),  
Undifferentiated sarcoma (M88053), Desmoplastic small round cell tumor (M88063), Fibrosarcoma (M88103),  
Infantile fibrosarcoma (M88143), Synovial sarcoma, spindle cell (M90413), Clear cell sarcoma (M90443)
Leiomyosarcoma (M88903), Epithelioid leiomyosarcoma (M88913)
Hemangiosarcoma (M81203), Malignant fibrous histiocytoma (M88303), Well-differentiated liposarcoma (M88513), 
Myxoid liposarcoma (M88523), Pleomorphic liposarcoma (M88543), Mixed liposarcoma (M88553), Dedifferentiated 
liposarcoma (M88583), Rhabdomyosarcoma (M89003), Pleomorphic rhabdomyosarcoma (M89013), Embryonal  
rhabdomyosarcoma (M89103), Hemangiopericytoma (M91503), Peripheral neuroectodermal tumor (M93643),  
Malignant peripheral nerve sheath tumor (M95403), Malignant neurilemoma (M95603), Kaposi’s sarcoma (M91403)
4. Gastrointestinal stromal sarcoma (M89363)
5. Melanoma Malignant melanoma (M87203), Nodular melanoma (M87213), Amelanotic melanoma (M87303), Malignant melanoma 
in junctional nevus (M87403), Epitheloid cell melanoma (M87713), Spindle cell melanoma (M87723)
6. Lymphoma Malignant lymphoma (M95903), Non-Hodgkin lymphoma (M95913), small B lymphocytic lymphoma (M96703), Large 
B-cell diffuse lymphoma (M96803), Large B-cell diffuse immunoblastic lymphoma (M96843), Mantle cell lymphoma 
(M96743), Burkitt lymphoma (M96873), Follicular lymphoma (M96903), Grade 1 follicular lymphoma (M96953), 
Grade 2 follicular lymphoma (M96913), Grade 3 follicular lymphoma (M96983), Marginal zone B-cell lymphoma 
(M96993), Mature T-cell lymphoma (M97023), Intestinal T-cell lymphoma (M97173), Anaplastic large cell lymphoma 
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nosed as regional and distant disease. Due to the limitation of the 
National Cancer Registry, information about prognosis, including 
survival and recurrence, was not available. However, carcinomas, 
lymphomas, and melanomas were commonly diagnosed at ad-
vanced stages. 
DISCUSSION
In this study, we analyzed the incidence of colorectal nonadeno-
carcinoma in Korea. Compared to adenocarcinoma, nonadeno-
carcinoma in Korea showed some characteristic features. Colorec-
tal nonadenocarcinoma accounted for 5.43% of all colorectal ma-
lignancies. The incidence of nonadenocarcinoma in Korea was 
much lower than that of adenocarcinoma. The age-standardized 
Table 2. Demographic features of nonadenocarcinoma patients (2007–
2016)
Category No. (%)
Total malignancy of colon and rectum 267,142 (100)
   Nonadenocarcinoma patients 14,495 (5.43)
   Adenocarinoma patients 252,647 (94.57)
Sex
   Male 8,760 (60.43)
   Female 5,735 (39.57)
Histologic category
   1. Carcinoma 1,454 (10.03)
      1.1. Squamous cell carcinoma 288 (1.99)
      1.2. Other specified carcinoma 1,166 (8.04)
   2. Neuroendocrine tumor (NET) 10,919 (75.33)
      2.1. NET 9,585 (66.13)
      2.2. Neuroendocrine carcinoma 1,334 (9.20)
   3. Sarcoma 156 (1.08)
      3.1. Sarcoma, not otherwise specified 35 (0.24)
      3.2. Leiomyosarcoma 56 (0.39)
      3.3. Other specified sarcoma 65 (0.45)
   4. Gastrointestinal stromal sarcoma 393 (2.71)
   5. Melanoma 142 (0.98)
   6. Lymphoma 1,431 (9.87)
Age distribution (yr)
   0–19 101 (0.70)
   20–29 424 (2.93)
   30–39 2,061 (14.22)
   40–49 3,530 (24.35)
   50–59 3,991 (27.53)
   60–69 2,531 (17.46)
   70–79 1,480 (10.21)
   ≥ 80 377 (2.60)
Anatomic distribution
   Appendix 241 (1.66)
   Cecum 517 (3.57)
   Ascending colon 523 (3.61)
   Hepatic flexure 73 (0.50)
   Transverse colon 171 (1.18)
   Splenic flexure 16 (0.11)
   Descending colon 110 (0.76)
   Sigmoid colon 537 (3.70)
   Rectosigmoid colon 265 (1.83)
   Rectum 11,066 (76.34)
   Overlapping lesion 67 (0.46)




   Localized 10,155 (70.06)
   Regional 1,221 (8.42)
   Distant 1,138 (7.85)
   Unstaged 1,981 (13.67)
SEER, Surveillance, Epidemiology, and End Results.
(Continued to the next)
Table 3. The number of patients and incidence of colorectal nonade-
nocarcinoma in male
Histologic category No. (%)
Rate
CR ASR (95% CI)
Total malignancy of colon and  
rectum
160,367 (100) 63.85 46.66 (46.42–46.89)
   Nonadenocarcinoma patients 8,760 (5.46) 3.49 2.52 (2.47–2.58)
1. Carcinoma
   1.1. Squamous cell carcinoma 92 (1.05) 0.03 0.03 (0.02–0.03)
   1.2. Other specified carcinoma 670 (7.65) 0.26 0.19 (0.17–0.21)
2. Neuroendocrine tumor (NET)
   2.1. NET 5,932 (67.72) 2.36 1.69 (1.65–1.73)
   2.2. Neuroendocrine carcinoma 834 (9.52) 0.33 0.24 (0.21–0.26)
3. Sarcoma
   3.1. Sarcoma 21 (0.24) 0.01 0.01 (0.00–0.01)
   3.2. Leiomyosarcoma 32 (0.37) 0.01 0.01 (0.01–0.01)
   3.3. Other specified sarcoma 41 (0.47) 0.02 0.01 (0.01–0.01)
4.  Gastrointestinal stromal  
sarcoma 
202 (2.31) 0.08 0.06 (0.05–0.07)
5. Melanoma 52 (0.59) 0.02 0.01 (0.01–0.01)
6. Lymphoma 884 (10.09) 0.35 0.25 (0.25–0.26)
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incidence rates of colon adenocarcinoma in 2014 were 64.8 per 
100,000 in men and 44.0 in women [13]. We also found that non-
adenocarcinoma was relatively more frequent among younger pa-
tients than adenocarcinoma. The frequency of adenocarcinoma 
increases rapidly among patients in their 60s and is the highest 
among patients in their 60s, 70s, and 80s [13]. 
There has been little examination of the incidence and charac-
teristics of colorectal nonadenocarcinoma. DiSario et al. [14] re-
ported nonadenocarcinoma among 7,422 colon cancer patients in 
1994; only 255 patients (3%) were diagnosed with nonadenocar-
Table 4. The number of patients and incidence of colorectal nonadenocarcinoma in female
Histologic category No. (%)
Rate
CR ASR (95% CI)
Total malignancy of colon and rectum 106,775 (100) 42.58 25.03 (24.87–25.18)
   Nonadenocarcinoma patients 5,735 (5.37) 2.29 1.56 (1.52–1.60)
1. Carcinoma
   1.1. Squamous cell carcinoma 196 (3.41) 0.08 0.05 (0.05–0.05)
   1.2. Other specified carcinoma 496 (8.64) 0.20 0.13 (0.13–0.14)
2. Neuroendocrine tumor (NET)
   2.1. NET 3,653 (63.70) 1.46 1.03 (1.00–1.06)
   2.2. Neuroendocrine carcinoma 500 (8.72) 0.20 0.14 (0.13–0.14)
3. Sarcoma
   3.1. Sarcoma 14 (0.24) 0.01 0.00 (0.00–0.00)
   3.2. Leiomyosarcoma 24 (0.42) 0.01 0.01 (0.00–0.01)
   3.3. Other specified sarcoma 24 (0.42) 0.01 0.01 (0.00–0.01)
4. Gastrointestinal stromal sarcoma 191 (3.33) 0.08 0.05 (0.04–0.06)
5. Melanoma 90 (1.57) 0.04 0.02 (0.02–0.03)
6. Lymphoma 547 (9.54) 0.22 0.15 (0.14–0.15)
CR, crude rate per 100,000; ASR, age-standardized incidence rate; CI, confidence interval.
Table 5. Patient number and percentage of colorectal nonadenocarcinoma by age
Histologic type
Age (yr)
0–19 20–29 30–39 40–49 50–59 60–69 70–79 ≥ 80
Total malignancy of colon and rectum 207 (100) 1,256 (100) 7,550 (100) 25,354 (100) 59,936 (100) 73,702 (100) 70,088 (100) 29,049 (100)
   Nonadenocarcinoma patients 101 (48.79) 424 (33.76) 2,061 (27.30) 3,530 (13.92) 3,991 (6.66) 2,531 (3.43) 1,480 (2.11) 377 (1.30)
1. Carcinoma
   1.1. Squamous cell carcionma 2 (1.98) 1 (0.24) 6 (0.29) 33 (0.93) 66 (1.65) 68 (2.69) 74 (5.00) 38 (10.08)
   1.2. Other specified carcinoma 1 (0.99) 7 (1.65) 41 (1.99) 123 (3.48) 240 (6.01) 305 (12.05) 311 (21.01) 138 (36.60)
2. Neuroendocrine tumor (NET)
   2.1. NET 34 (33.66) 326 (76.89) 1,709 (82.92) 2,759 (78.16) 2,828 (70.86) 1,415 (55.91) 471 (31.82) 43 (11.41)
   2.2. Neuroendocrine tumor 6 (5.94) 31 (7.31) 164 (7.96) 316 (8.95) 383 (9.60) 235 (9.28) 166 (11.22) 33 (8.75)
3. Sarcoma
   3.1. Sarcoma 2 (1.98) 1 (0.24) 10 (0.49) 3 (0.08) 6 (0.15) 8 (0.32) 4 (0.27) 1 (0.27)
   3.2. Leiomyosarcoma 1 (0.99) 0 (0) 4 (0.19) 7 (0.20) 15 (0.38) 16 (0.63) 10 (0.68) 3 (0.80)
   3.3. Other specified sarcoma 0 (0) 0 (0) 1 (0.05) 22 (0.62) 16 (0.40) 14 (0.55) 17 (1.15) 4 (1.06)
4. Gastrointestinal stromal sarcoma 0 (0) 4 (0.94) 20 (0.97) 64 (1.81) 109 (2.73) 101 (3.99) 80 (5.41) 15 (3.98)
5. Melanoma 0 (0) 1 (0.24) 5 (0.24) 12 (0.34) 24 (0.60) 33 (1.30) 52 (3.51) 15 (3.98)
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cinoma. There were 75 patients (33%) diagnosed with squamous 
cell carcinoma, 74 patients (33%) with malignant NET, 37 patients 
(16%) with transitional cell-like tumor, 25 patients (11%) with 
lymphoma, 9 patients (4%) with sarcoma, and 2 patients (0.9%) 
with melanoma [14]. Because the most common colorectal ma-
lignancy is adenocarcinoma, most studies focus on adenocarci-
noma. Due to the rarity of nonadenocarcinoma cases, they are 
mainly reported as case series. This study is meaningful in that it 
is almost the first study in Korea on the incidence and clinical 
characteristics of each colorectal nonadenocarcinoma. 
Neuroendocrine carcinoma of the colorectum accounts for 0.6% 
of all colorectal malignancies [5] and occurs most frequently in 
patients from 60 to 89 years of age [8]. In this study, most NETs 
occurred in the rectum (93.07%). This is consistent with the fact 
that, in Asia, the rectum is a frequent location of NETs [15]. How-
ever, in western countries, NETs mostly occur in the proximal co-
Fig. 2. The proportion of nonadenocarcinoma by location. NET, neuroendocrine tumors; GIST, gastrointestinal stromal tumor.
Fig. 3. The SEER (Surveillance, Epidemiology and End Results) stage of nonadenocarcinoma. NET, neuroendocrine tumors; GIST, gastroin-
testinal stromal tumor.
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lon, including the cecum and ascending colon [16]. Neuroendo-
crine carcinoma has a male dominance and mean age at diagnosis 
around 50 years [16]. The incidence of NET in this study may be 
low compared to those found in other studies. The Korean Gas-
trointestinal Pathology Study Group suggested to diagnose 
colorectal grade 1 (G1) NETs with less than 1-cm size using D 
code, not C code [17]. Therefore, the diagnosis of malignant NET 
in Korea is conservative, and its incidence is less than that in other 
countries. In this study, we included G2 and G3 NETs, G1 NETs 
greater than 1 cm, and neuroendocrine carcinomas. 
Squamous cell carcinoma accounted for 0.11% of the colorectal 
cancers in this study, which is similar to the results of a previous 
study that reported an incidence of 0.20% to 0.85% [7]. Squamous 
cell carcinomas are frequently located in the rectum because they 
can originate from the anal canal [18]. Adenosquamous carci-
noma accounts for 0.03% to 0.18% of all colorectal malignancies 
[19], and cloacogenic carcinoma was reported in only 7 patients 
from 1977 to 2009 [20]. 
In previous studies, sarcoma accounted for 0.1% of all colorectal 
malignancies [8]. In this study, sarcoma accounted for 0.06% of all 
colorectal malignancies. Sarcoma is reported to be most fre-
quently diagnosed in patients in their 60s and 70s [21]. Leiomyo-
sarcoma in the colon is reported to account for 1% to 2% of all 
gastrointestinal malignancies [22]. A study using data from the 
American Cancer Registry showed that leiomyosarcoma was the 
most frequent sarcoma in the colon and rectum (57.5%), followed 
by sarcoma (16.2%) [23]. This study showed similar results.
Colorectal GIST accounts for 5% to 6% of all gastrointestinal 
tract GIST [24]. Colonic GIST shows male predominance, and 
the mean age at diagnosis is 67.5 years [25]. Due to the rarity of 
colorectal GIST, there are no reports about other clinical features 
of confined colorectal GIST. 
In a previous study of 12 melanoma patients, there was a male 
predominance (1.4:1), and it was most common in the cecum and 
ascending colon [26]. However, in this study, there was a female 
predominance of melanoma and it was most common in the rec-
tum. In this study, melanoma occurred only in the distal colon, 
including the sigmoid colon, rectosigmoid junction, and rectum.
Lymphoma occurred more frequently in the proximal colon, in-
cluding the appendix, cecum, and ascending colon. Hangge et al. 
[27] reported that the most frequent location of lymphoma was 
the cecum, followed by the rectum and sigmoid colon. Lym-
phoma occurred more in men in this study. Chang [28] reported 
that primary colonic lymphoma showed male dominance. Pri-
mary colonic lymphoma accounts for 0.2% to 0.6% of all colorec-
tal malignancies [29]. Most colonic lymphomas were reported to 
be B-cell lymphoma, but T-cell lymphoma has also been reported 
in Asia [30]. In this study, most lymphomas were B-cell lympho-
mas, although we also observed mature T-cell lymphoma and in-
testinal T-cell lymphoma. 
This is the first nationwide analysis of colorectal nonadenocarci-
noma in Korea. We identified differences in nonadenocarcinoma 
incidence based on demographic factors. There was a limitation 
in that the data only contained information on stage using SEER 
and not the TNM staging system; therefore, it was impossible to 
analyze detailed stage-specific features of each tumor. Further, as 
the National Cancer Registry showed only the incidence result, 
statistical analysis of each category was impossible. However, we 
were able to identify incidence based on different characteristics 
in nonadenocarcinoma as compared to adenocarcinoma; for ex-
ample, nonadenocarcinoma was relatively more prevalent in 
younger patients than adenocarcinoma. 
In conclusion, this study was the first to examine the incidence 
of colorectal nonadenocarcinoma in Korea. The characteristics of 
each nonadenocarcinoma, including carcinoma-except adenocar-
cinoma, NET, sarcoma, GIST, melanoma, and lymphoma, were 
identified. Cancer prevention and future management projects 
should be based on the basic characteristics of colorectal nonade-
nocarcinoma identified in this study. 
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